Business
Compass Therapeutics, Inc.: We have never generated revenue from product sales and may never be profitable.
Net income decreased 34.7% to ($66.5M), while Operating cash flow decreased 9.6% to ($49.1M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($66.5M)Watch
- Cash generation — Free cash flow ($49.2M)Note
- Accounting — No applicable forensic screenNote
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Leadership changes
From Compass Therapeutics, Inc.'s own filings, the day they're filed.
- Neil Lerner · Principal Accounting Officer Simultaneous to the appointment of Mr · appointmenteff. 2024-12-09
- Thomas Schuetz · President · appointmenteff. 2024-05-28
- Vered Bisker-Leib · Chief Executive Officer · departureeff. 2024-05-28
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-01
- 8-K · Company announcement2026-06-23
- 8-K · Company announcement2026-06-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Compass Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.